Vivani Medical, Inc. (NASDAQ:VANI) Sees Significant Decline in Short Interest

30 Dec 2025, 08:42 by Scott Moore · The Cerbat Gem

Vivani Medical, Inc. (NASDAQ:VANI – Get Free Report) was the recipient of a large decline in short interest in the month of December. As of December 15th, there was short interest totaling 220,276 shares, a decline of 29.4% from the November 30th total of 312,110 shares. Based on an average trading volume of 141,464 shares, the short-interest ratio is presently 1.6 days. Currently, 0.6% of the shares of the company are short sold. Currently, 0.6% of the shares of the company are short sold. Based on an average trading volume of 141,464 shares, the short-interest ratio is presently 1.6 days.

Insider Activity at Vivani Medical

In related news, Director Gregg Williams bought 1,737,765 shares of the stock in a transaction that occurred on Monday, December 15th. The shares were bought at an average cost of $1.14 per share, for a total transaction of $1,981,052.10. Following the completion of the transaction, the director owned 24,826,344 shares of the company’s stock, valued at approximately $28,302,032.16. This trade represents a 7.53% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders acquired 8,916,996 shares of company stock valued at $11,943,153. Corporate insiders own 46.40% of the company’s stock.

Institutional Investors Weigh In On Vivani Medical

Large investors have recently made changes to their positions in the company. Citadel Advisors LLC purchased a new stake in shares of Vivani Medical in the third quarter worth about $26,000. Panagora Asset Management Inc. bought a new stake in Vivani Medical in the 2nd quarter worth approximately $25,000. Finally, Susquehanna International Group LLP increased its stake in Vivani Medical by 100.5% in the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock worth $46,000 after acquiring an additional 16,200 shares during the last quarter. 6.78% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

VANI has been the topic of a number of analyst reports. Wall Street Zen raised Vivani Medical to a “sell” rating in a research report on Saturday, November 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vivani Medical in a research report on Tuesday, October 14th. Zacks Research raised shares of Vivani Medical from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 12th. Finally, HC Wainwright restated a “buy” rating and set a $4.00 target price on shares of Vivani Medical in a research note on Tuesday, September 2nd. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $4.00.

View Our Latest Report on VANI

Vivani Medical Price Performance

Vivani Medical stock opened at $1.25 on Tuesday. Vivani Medical has a 1 year low of $0.91 and a 1 year high of $1.92. The firm’s 50 day moving average price is $1.45 and its 200-day moving average price is $1.39. The stock has a market cap of $91.19 million, a P/E ratio of -2.78 and a beta of 3.24.

Vivani Medical (NASDAQ:VANI – Get Free Report) last issued its earnings results on Thursday, November 13th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. As a group, equities analysts expect that Vivani Medical will post -0.41 EPS for the current year.

Vivani Medical Company Profile

(Get Free Report)

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.